{"nctId":"NCT00200967","briefTitle":"Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)","startDateStruct":{"date":"2004-12"},"conditions":["Asthma"],"count":87,"armGroups":[{"label":"B16 Arg/Arg","type":"EXPERIMENTAL","interventionNames":["Drug: salmeterol","Drug: beclomethasone HFA"]},{"label":"B16 Gly/Gly","type":"EXPERIMENTAL","interventionNames":["Drug: salmeterol","Drug: beclomethasone HFA"]}],"interventions":[{"name":"salmeterol","otherNames":["Serevent"]},{"name":"beclomethasone HFA","otherNames":["QVAR"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, ages 18 and older\n* Clinical history consistent with asthma\n* For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted, methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol\n* For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted, methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol\n* Genotype eligibility (determined during screening)\n\nExclusion Criteria:\n\n* Smoker (total smoking history must be less than 10 pack years)\n* Significant unstable medical condition other than asthma\n* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the past 10 years\n* Pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Morning (AM) Peak Expiratory Flow (PEF) Rate","description":"Change between placebo salmeterol and active salmeterol for AM PEF rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21","spread":null},{"groupId":"OG001","value":"-22","spread":null}]}]}]},{"type":"SECONDARY","title":"Evening (PM) Peak Expiratory Flow (PEF) Rate","description":"Change between placebo salmeterol and active salmeterol for PM PEF rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25","spread":null},{"groupId":"OG001","value":"-24","spread":null}]}]}]},{"type":"SECONDARY","title":"Peak Expiratory Flow (PEF) Variability","description":"Change between placebo salmeterol and active salmeterol for PEF variability, where PEF variability is defined as 100% x (PM PEF - AM PEF)/(PM PEF)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Symptoms","description":"Change between placebo salmeterol and active salmeterol for asthma symptoms (0=absent, 1=mild, 2=moderate, 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication (Ipratropium and Albuterol) Use","description":"Change between placebo salmeterol and active salmeterol for rescue medication use","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Spirometry Forced Expiratory Volume in One Second (FEV1), Pre-bronchodilator","description":"Change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":null},{"groupId":"OG001","value":"-0.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Spirometry Forced Vital Capacity (FVC), Pre-bronchodilator","description":"Change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":null},{"groupId":"OG001","value":"-0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Spirometry Peak Expiratory Flow (PEF) Rate, Pre-bronchodilator","description":"Change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17","spread":null},{"groupId":"OG001","value":"-17","spread":null}]}]}]},{"type":"SECONDARY","title":"Exhaled Nitric Oxide (eNO)","description":"Change between placebo salmeterol and active salmeterol for eNO","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"-0.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Exhaled Breath Condensate (EBC)","description":"Change between placebo salmeterol and active salmeterol for EBC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":null},{"groupId":"OG001","value":"-0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Methacholine Provocative Concentration 20 (PC20)","description":"Change between placebo salmeterol and active salmeterol for methacholine PC20","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"-1.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Asthma Control Questionnaire (ACQ)","description":"Change between placebo salmeterol and active salmeterol for ACQ, where ACQ ranges from 0 (best asthma control) to 6 (worst asthma control).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":42},"commonTop":["respiratory infection"]}}}